Gilead Sciences Hits 6-week Low

Trading Economics04:54

Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus

Benzinga03:07

Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%

MT Newswires01/08 20:16

Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead

Benzinga01/08 20:04

Looking Into Gilead Sciences's Recent Short Interest

Benzinga01/08 02:00

Gilead Sciences, Inc. (NASDAQ:GILD) Is a Favorite Amongst Institutional Investors Who Own 86%

Simply Wall St01/07 21:48